PEG

Top-down strategic PRINT technique

Conjugated antibody

-

HeLa, Ramos, H460, SK-OV-3, HepG2, LNCaP

(267 ± 49) - (292 ± 76)

(−35.6 ± 1.3) - (39.9 ± 1.7)

[67]

PEG-PCL

Dry-down method

-

-

MDA-MB-468, MCF-7

(26.4 ± 0.7) - (60.9 ± 0.7)

(−5.1) - (−7.3)

[68]

PEG-PCL

Solvent evaporation

Paclitaxel

Sodium Cholate

U87 MG, BCECs

<100

(−3.08 ± 0.94) - (−3.28 ± 0.75)

[69]

PEG-PHDCA

Nanoprecipitation

Nile red

Pluronic F68

RBECs

140 - 146

−20

[70]

PEG-PLA

Solvent displacement

-

Solutol^® HS 15

HeLa

89.8 ± 4, 96.4 ± 6

32.8 ± 8, −26 ± 1

[71]

PEG-PLA

Emulsion-solvent evaporation

BSA, Coumarin-6

Sodium Cholate

Rat BCECs, Astrocytes

80.4 - 84.4

(−8)-(−17)

[72]

PEG-PLA

Solvent displacement

Coumarin-6

Solutol^® HS 15

MDCK

(89.8 ± 4) -

(96.36 ± 6)

(−29 ± 7) - (45.46 ± 2)

[73]

PEG-PLA

Nanoprecipitation

Cisplatin

-

A2780

(86 ± 2)

−33 ± 1.2

[74]

PEG-PLGA

Simple emulsion, Interfacial deposition

Paclitaxel

Sodium Cholate

HeLA

190 ± 4.5, and 112 ± 4

−7.76 ± 2.6, −0.556 ± 5.7

[75]

PEG-Trimethyl Chitosan

Self-assembly utilizing electrostatic interactions

Insulin

-

Caco-2

(203.9 ± 7.2) - (376.4 ± 10.3)

(7.4 ± 0.3) - (21.4 ± 0.3)

[76]

PEO-b-PMA

-

Cisplatin, Doxorubicin

-

A2780, A549

(93.8 ± 8.4) - (176.5 ± 6.0)

(−29.2 ± 1.5) - (−2.1 ± 1.0)

[77]

PLA

Diafiltration

Trans-retinoic acid

Poly(vinyl benzyl lactonamide)

Hepatocytes

287.7

-

[78]

PLA

Emulsion-solvent evaporation

Rhodamine, Selectin grafted

Sucrose solution containing Tween 20, PEG-Laurate

HUVEC

173 ± 23, 168 ± 37

−25.7, −19.2

[79]

PLA

Solvent evaporation

Doxorubicin

-

SLK

45 ± 8 - 47 ± 4

-

[80]

PLA, PLGA

Multiple emulsion-solvent evaporation

Plasmid DNA

PVA

MCF-7, PC-3

(270 ± 1) - (1207 ± 30)

(−6.5 ± 2) - (−31.3 ± 2)

[81]

PLA, PLGA

Solvent deposition

Docetaxel

Tween 80

-

(100.7 ± 2.9) - (179.4 ± 1.7), (98.7 ± 1.7) - (172.0 ± 4.9)

(−38) - (−24), < (−10)

[82]

PLGA

Double emulsion-solvent evaporation

DNA

PVA

COS-7, HEK-293

(70±2)-(202±9)

(−20.6 ± 2) - (−20.8 ± 2)

[83]

PLGA

Multiple emulsion-solvent evaporation

BSA

PVA

HASMC

380 - 522

(−0.8 ± 2.3) - (−15.4 ± 0.8)

[84]

PLGA

Emulsion-solvent evaporation

Paclitaxel

PVA

MCF-7 and MCF-7/Adr

216

−8.12 ± 2.8

[85]

PLGA

Double emulsion-solvent diffusion

Cystatin

PVA

MCF-7, MCF-10A neoT, Caco-2, U-937

320 - 360

−25

[86]

PLGA

Emulsion-solvent evaporation

BSA, Coumarin-6

PVA

HUVEC

277 - 372

−10.4

[87]

PLGA

Emulsion-solvent evaporation

Paclitaxel

PVA

A549, H1299, CCL-186

(228.2 ± 0.6) - (330.7 ± 2.9)

(−4.3 ± 0.3) - (−17.9 ± 1)

[88] [89]

PLGA

Emulsion-solvent diffusion

FITC-WGA, FITC-BSA

PVA

A549

246, 356

~(−4)

[90]

PLGA

Solvent evaporation

Camptothecin

PVA

HCT116

(116.5 ± 1.6) - (187.1 ± 1.1)

-

[91]

PLGA

-

Loperamide, Rhodamine-123

-

Tail vein in rats

140 - 180

−20

[92]

PLGA

Interfacial deposition

Paclitaxel

Poloxamer 188

NCI-H69, SCLC

(117 ± 2) - (160 ± 2)

(−33.4 ± 1.8) - (−23.1 ± 3.7)

[93]

PLGA

Direct dialysis

Paclitaxel

Vitamin E TPGS

C6 glioma

(280 ± 28) - (310 ± 28)

(−20) - (−40)

[94]

PLGA

Modified emulsification- solvent diffusion

Docetaxel

PVA

T47D, MCF-7, SKOV3, A549

172 - 178

−12.2 ± 0.6

[95]